Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
Muscle-invasive bladder cancer
Pathological staging
Patient outcome
Perivesical extension
Tumor invasion front
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
01
11
2020
accepted:
08
04
2021
pubmed:
22
4
2021
medline:
19
2
2022
entrez:
21
4
2021
Statut:
ppublish
Résumé
The value of bladder cancer (BC) substaging into macroscopic (pT3b) and microscopic (pT3a) perivesical fat extension in lymph node (Ln)-negative patients is controversially discussed and limited evidence for prognostic relevance of additional histopathological factors in pT3 BC exists. We evaluated the prognostic value of pT3 substaging and established pathological and clinical parameters with focus on tumor invasive front (TIF) and tumor size. Specimens of 52 patients treated with radical cystectomy (RC) for pT3 a/b muscle-invasive BC were reviewed and re-evaluated by a pathologist specialized in uropathology. Clinical variables and standard histopathologic characteristics were assessed including TIF and tumor size. Their value as prognosticators for overall survival (OS) and recurrence-free survival (RFS) was evaluated. Mean age of patients was 67.55 years. Tumors were staged pT3a in 28 patients (53.8%) and pT3b in 24 (46.8%). Median OS was 34.51 months. Median tumor size was 3.2 cm, median TIF was 11.0 mm. Differences in OS between pT3a and pT3b were not significant (p = 0.45). Carcinoma in situ (CIS) and lymphovascular invasion (LVI) were significantly associated with pT3b tumors. Univariate analysis could not identify pathological prognosticators like TIF or tumor size for OS and RFS (p for all > 0.05). No significant differences in OS or RFS were observed comparing Ln-negative pT3 BC following radical cystectomy. Additional pathologic variables like TIF could not be identified as prognosticator. Relevance of pT3 BC substaging needs reevaluation in larger prospective cohorts.
Identifiants
pubmed: 33881556
doi: 10.1007/s00345-021-03697-3
pii: 10.1007/s00345-021-03697-3
pmc: PMC8571207
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4021-4027Informations de copyright
© 2021. The Author(s).
Références
Cancer. 2009 Feb 15;115(4):770-5
pubmed: 19152431
J Urol. 2004 Feb;171(2 Pt 1):640-5
pubmed: 14713777
Lymphology. 1996 Sep;29(3):118-25
pubmed: 8897356
J Urol. 2011 Apr;185(4):1216-21
pubmed: 21334687
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Urol. 2012 Nov;188(5):1706-11
pubmed: 22998911
Urology. 2010 Oct;76(4):908-13; discussion 914
pubmed: 20709375
J Cancer. 2015 Jun 29;6(8):750-8
pubmed: 26185537
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
BMC Cancer. 2011 Aug 04;11:336
pubmed: 21816094
Urology. 2008 Sep;72(3):706-10
pubmed: 18342921
Int Urol Nephrol. 2013 Apr;45(2):387-93
pubmed: 23338846
BJU Int. 2012 Dec;110(11):1736-41
pubmed: 22998125
J Urol. 2010 Aug;184(2):470-4
pubmed: 20620401
Adv Anat Pathol. 2017 May;24(3):113-127
pubmed: 28398951